Optimi Health Corp. announced it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that Optimi?s formulated MDMA meets Good Manufacturing Practice (GMP) specifications. Optimi has also completed GMP process validation for the encapsulation of the active pharmaceutical ingredient (API) in both 40mg and 60mg dosage formats for batch sizes up to 1,000 capsules during GMP production.

The COA for the finished product affirms important data and analytics around content uniformity, microbial and water content, and dosage strength. Additionally, Optimi?s ongoing stability testing demonstrated that the MDMA API used to make both dosages remains stable within the capsules under both real-time and accelerated storage conditions for up to three months. The MDMA API used to produce the releasable GMP capsules has a purity level of 99.95%.